Phase 3 Lymphoma Trial, Recruiting NCT02836158 Sponsor: Navy General Hospital, Beijing Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT02836158
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a type of blood cancer called non-Hodgkin's lymphoma (NHL), confirmed by a tissue biopsy.

Who may not be able to join:

  • People whose lymphoma has spread to areas of the body other than the brain, the lining of the brain (meninges), the fluid around the brain and spine (CSF), or the eyes.
  • People under 18 years old or over 75 years old.
  • People whose bone marrow is not producing enough blood cells — specifically, those with low levels of white blood cells, platelets, or red blood cells (confirm with trial site for exact values).
  • People known to have a condition that weakens the immune system, such as HIV type I infection.
  • People who have had any previous cancer diagnosis.
  • People whose kidneys are not filtering blood well enough (a kidney function measure called creatinine clearance must be at least 60 mL/min — confirm with trial site).
  • People with significant heart failure (classified as NYHA grade IIIB or IV — confirm with trial site).
  • People with an infection that is not currently under control.
  • People with active lung or liver disease that is not being adequately managed.
  • People who have previously received treatment for this type of brain cancer (called primary central nervous system lymphoma or PCNSL), unless that treatment was only corticosteroids (a type of anti-inflammatory medication).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Liren Qian, M.D., Navy General Hospital, Beijing

Phone: +861066957676

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Navy General Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
1 September 2010
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov